Molecular Portrait of GISTs Associated With Clinicopathological Features: A Retrospective Study With Molecular Analysis by a Custom 9-Gene Targeted Next-Generation Sequencing Panel

被引:4
作者
Qian, Haoran
Yan, Na
Hu, Xiaotong
Jiang, Junchang
Cao, Zhengzheng
Shen, Dan
机构
[1] Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou
[2] Dian Diagnostics Group Co., Ltd, Hangzhou
[3] Key Laboratory of Clinical, Vitro Diagnostic Techniques of Zhejiang Province, Hangzhou
[4] Department of Pathology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou
关键词
gastrointestinal stromal tumors; molecular subtypes; clinicopathological features; next-generation sequencing; target therapy; GASTROINTESTINAL STROMAL TUMORS; KIT GENE; MUTATIONS; IMATINIB; AVAPRITINIB; DIAGNOSIS;
D O I
10.3389/fgene.2022.864499
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Objectives: The study aims to investigate genetic characterization of molecular targets and clinicopathological features with gastrointestinal stromal tumors based on targeted next-generation sequencing.Materials and Methods: We selected 106 patients with GISTs from Sir Run Run Shaw Hospital between July 2019 and March 2021. FFPE samples and paired blood samples were obtained from these patients who underwent excision of the tumor. A customized targeted-NGS panel of nine GIST-associated genes was designed to detect variants in the coding regions and the splicing sites of these genes.Results: In total, 106 patients with a GIST were included in the study which presented with various molecular driver alterations in this study. KIT mutations occurred most often in GISTs (94/106, 95.92%), followed by point mutations in PDGFRA. KIT or PDGFRA mutations were detected to be mutually exclusive in the GIST. A total of eight patients with wide-type KIT/PDGFRA were characterized as WT-GISTs, according to clinical diagnosis which included six quadruple-WT GISTs, 1 BRAF-mutant, and 1 NF1-mutant GIST. In KIT exon 11, the most common mutation type was the codon Mutation (in-frame deletion or indels), whereas the missense mutation was the dominant type in KIT exon 13 and KIT exon 17. All variations in KIT exon 11 observed in this study were concentrated at a certain position of codon 550 to codon 576. Mutation in KIT exon 9 was mostly located at codon 502-503. Two germline pathogenic mutations were detected: NF1-R681* and KRAS-T58I. NF1-L591P was a germline mutation to be identified for the first time and is not recorded in the database. The frequency of driving mutations differed between the primary anatomical site in the GIST (p = 0.0206). KIT exon 11 mutants had a lower proliferation index of Ki67 (68.66%,<= 5%), while 50.00% of KIT exon 9 mutants had the Ki67 status greater than 10%.Conclusion: The occurrence and development of a GIST is driven by different molecular variations. Resistance to TKIs arises mainly with resistance mutations in KIT or PDGFRA when they are the primary drivers. Targeted NGS can simultaneously and efficiently detect nine GIST-related gene mutations and provide reference for clinicians' individualized diagnosis and treatment. Our results have important implications for clinical management.
引用
收藏
页数:12
相关论文
共 35 条
  • [1] Clinical and pathological features of "small" GIST (≤2 cm). What is their prognostic value?
    Angel Fernandez, Juan
    Jesus Gomez-Ruiz, Alvaro
    Olivares, Vicente
    Ferri, Belen
    Dolores Frutos, Maria
    Soria, Teresa
    Jose Gil, Pedro
    Torres, Gloria
    Parrilla, Pascual
    [J]. EJSO, 2018, 44 (05): : 580 - 586
  • [2] Gastrointestinal stromal tumours
    Blay, Jean-Yves
    Kang, Yoon-Koo
    Nishida, Toshiroo
    von Mehren, Margaret
    [J]. NATURE REVIEWS DISEASE PRIMERS, 2021, 7 (01)
  • [3] Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic
    Boikos, Sosipatros A.
    Pappo, Alberto S.
    Killian, J. Keith
    LaQuaglia, Michael P.
    Weldon, Chris B.
    George, Suzanne
    Trent, Jonathan C.
    von Mehren, Margaret
    Wright, Jennifer A.
    Schiffman, Josh D.
    Raygada, Margarita
    Pacak, Karel
    Meltzer, Paul S.
    Miettinen, Markku M.
    Stratakis, Constantine
    Janeway, Katherine A.
    Helman, Lee J.
    [J]. JAMA ONCOLOGY, 2016, 2 (07) : 922 - 928
  • [4] Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry
    Boonstra, P. A.
    Steeghs, N.
    Farag, S.
    van Coevorden, F.
    Gelderblom, H.
    Grunhagen, D. J.
    Desar, I. M. E.
    van der Graaf, W. T. A.
    Bonenkamp, J. J.
    Reyners, A. K. L.
    van Etten, B.
    [J]. EJSO, 2019, 45 (03): : 410 - 415
  • [5] Bradea C., 2021, JURNALUL CHIRURG, V17, P46, DOI [10.7438/jsurg.2021.01.06, DOI 10.7438/JSURG.2021.01.06]
  • [6] Gastrointestinal stromal tumours: origin and molecular oncology
    Corless, Christopher L.
    Barnett, Christine M.
    Heinrich, Michael C.
    [J]. NATURE REVIEWS CANCER, 2011, 11 (12) : 865 - 878
  • [7] Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST)
    Daniels, Marc
    Lurkin, Irene
    Pauli, Roland
    Erbstoesser, Erhard
    Hildebrandt, Uwe
    Hellwig, Karsten
    Zschille, Uwe
    Lueders, Petra
    Krueger, Gabriele
    Knolle, Juergen
    Stengel, Bernd
    Prall, Friedrich
    Hertel, Kay
    Lobeck, Hartmut
    Popp, Brigitte
    Theissig, Franz
    Wuensch, Peter
    Zwarthoff, Ellen
    Agaimy, Abbas
    Schneider-Stock, Regine
    [J]. CANCER LETTERS, 2011, 312 (01) : 43 - 54
  • [8] KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
    Debiec-Rychter, Maria
    Sciot, Raf
    Le Cesne, Axel
    Schlemmer, Marcus
    Hohenberger, Peter
    van Oosterom, Allan T.
    Blay, Jean-Yves
    Leyvraz, Serge
    Stul, Michel
    Casali, Paolo G.
    Zalcberg, John
    Verweij, Jaap
    Van Glabbeke, Martine
    Hagemeijer, Anne
    Judson, Ian
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) : 1093 - 1103
  • [9] Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
    Demetri, George D.
    van Oosterom, Allan T.
    Garrett, Christopher R.
    Blackstein, Martin E.
    Shah, Manisha H.
    Verweij, Jaap
    McArthur, Grant
    Judson, Ian R.
    Heinrich, Michael C.
    Morgan, Jeffrey A.
    Desai, Jayesh
    D Fletcher, Christopher
    George, Suzanne
    Bello, Carlo L.
    Huang, Xin
    Baum, Charles M.
    Casali, Paolo G.
    [J]. LANCET, 2006, 368 (9544) : 1329 - 1338
  • [10] Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing
    Ducimetiere, Francoise
    Lurkin, Antoine
    Ranchere-Vince, Dominique
    Decouvelaere, Anne-Valerie
    Peoc'h, Michel
    Istier, Luc
    Chalabreysse, Philippe
    Muller, Christine
    Alberti, Laurent
    Bringuier, Pierre-Paul
    Scoazec, Jean-Yves
    Schott, Anne-Marie
    Bergeron, Christophe
    Cellier, Dominic
    Blay, Jean-Yves
    Ray-Coquard, Isabelle
    [J]. PLOS ONE, 2011, 6 (08):